Analyst: New study confirms that Eli Lilly's tirzepatide is a good product
Eli Lilly has published strong results for its study of the diabetes treatment tirzepatide, which took up the last piece of the puzzle needed for an FDA application, Sydbank analyst Søren Løntoft Hansen says.
BY RITZAU FINANS, TRANSLATED BY CATHERINE BRETT
On Thursday, Eli Lilly released the results of its study of type 2 diabetes treatment tirzepatide, which will compete with Novo Nordisk's Ozempic.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly on tirzepatide data: Surpasses our expectations
For subscribers
.jpg&w=384&q=75)
